Qianhong Bio-pharma(SZ:002550)2022-12-08 01:24Group 1: Company Strategy and Development - The company has decided to suspend its plan to build hospitals and instead participate in the reform of public hospitals in Changzhou, aligning with national healthcare reform policies [3] - Future development will focus on both the biopharmaceutical industry and the broader health industry, with plans to establish a medical platform through the acquisition of a public hospital [3][4] - The company aims to gradually enter the mobile healthcare sector and build a multi-tiered medical network to serve patients, while also establishing a high-end elderly care service [3] Group 2: Product Development and Market Performance - The price of ordinary heparin preparations has decreased due to domestic bidding impacts, but the company plans to upgrade its production and export capabilities [5] - Despite a decline in revenue from heparin raw materials, the gross profit margin has increased due to a larger decrease in unit costs compared to price drops [6] - Sales of the product "Yikai" have seen an increase in both volume and revenue, although prices have been affected by secondary negotiations with some hospitals [6] - The compound digestive enzyme product has experienced over 70% growth from January to September, primarily sold through hospital channels [7] - The domestic formulation sales team currently consists of over 600 members [8] Group 3: Market and Economic Outlook - The company discussed recent performances in the capital market and macroeconomic conditions with attendees [8]